These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1498179)

  • 1. [Evolution of antibiotic sensitivity in Brucella melitensis].
    Pulido A; Liñares J; Escribano E; Alonso T; Ariza J
    Enferm Infecc Microbiol Clin; 1992 Jan; 10(1):56-7. PubMed ID: 1498179
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of Brucella species isolated from proven brucellosis patients in Izmir, Turkey.
    Köse S; Kiliç S; Ozbel Y
    J Basic Microbiol; 2005; 45(4):323-7. PubMed ID: 16028204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis.
    López-Merino A; Contreras-Rodríguez A; Migranas-Ortiz R; Orrantia-Gradín R; Hernández-Oliva GM; Gutiérrez-Rubio AT; Cardeñosa O
    Scand J Infect Dis; 2004; 36(9):636-8. PubMed ID: 15370648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antimicrobial susceptibility of Brucella species.
    Baykam N; Esener H; Ergönül O; Eren S; Celikbas AK; Dokuzoguz B
    Int J Antimicrob Agents; 2004 Apr; 23(4):405-7. PubMed ID: 15081093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of Brucella melitensis to fluoroquinolones.
    Qadri SM; Akhtar M; Ueno Y; al-Sibai MB
    Drugs Exp Clin Res; 1989; 15(10):483-5. PubMed ID: 2632216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp.
    Turan H; Arslan H; Azap OK; Serefhanoğlu K; Uncu H
    Int J Antimicrob Agents; 2007 Aug; 30(2):186-7. PubMed ID: 17462865
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of ciprofloxacin resistance in Brucella melitensis.
    al-Sibai MB; Qadri SM
    J Antimicrob Chemother; 1990 Feb; 25(2):302-3. PubMed ID: 2329110
    [No Abstract]   [Full Text] [Related]  

  • 8. Rifampicin resistance in a strain of Brucella melitensis after treatment with doxycycline and rifampicin.
    De Rautlin de la Roy YM; Grignon B; Grollier G; Coindreau MF; Becq-Giraudon B
    J Antimicrob Chemother; 1986 Nov; 18(5):648-9. PubMed ID: 3804888
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotypes and antimicrobial susceptibilities of Brucella isolates.
    Bodur H; Balaban N; Aksaray S; Yetener V; Akinci E; Colpan A; Erbay A
    Scand J Infect Dis; 2003; 35(5):337-8. PubMed ID: 12875523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug sensitivity of Brucella melitensis.
    Kaur YP; Gupta KG
    Indian J Exp Biol; 1972 May; 10(3):242-3. PubMed ID: 4651251
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro activity of azithromycin and tetracycline against 358 clinical isolates of Brucella melitensis.
    Landínez R; Liñares J; Loza E; Martínez-Beltrán J; Martín R; Baquero F
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):265-7. PubMed ID: 1317801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actual antibiotic resistance pattern of Brucella melitensis in central Anatolia. An update from an endemic region.
    Tanyel E; Coban AY; Koruk ST; Simsek H; Hepsert S; Cirit OS; Tulek N
    Saudi Med J; 2007 Aug; 28(8):1239-42. PubMed ID: 17676210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Short communication: Investigation of in vitro antibiotic susceptibility of Brucella melitensis].
    Alişkan H; Turunç T; Demiroğlu YZ; Colakoğlu S; Arslan H
    Mikrobiyol Bul; 2008 Jan; 42(1):125-9. PubMed ID: 18444570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic and selected resistance to antibiotics binding the ribosome: analyses of Brucella 23S rrn, L4, L22, EF-Tu1, EF-Tu2, efflux and phylogenetic implications.
    Halling SM; Jensen AE
    BMC Microbiol; 2006 Oct; 6():84. PubMed ID: 17014718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline: its potential for treatment of brucellosis.
    Dizbay M; Kilic S; Hizel K; Arman D
    Scand J Infect Dis; 2007; 39(5):432-4. PubMed ID: 17464866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of several antibiotic combinations against Brucella melitensis Rev 1 experimental infection in BALB/c mice.
    Grilló MJ; De Miguel MJ; Muñoz PM; Marín CM; Ariza J; Blasco JM
    J Antimicrob Chemother; 2006 Sep; 58(3):622-6. PubMed ID: 16849379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis.
    Navarro E; Segura JC; Castaño MJ; Solera J
    Clin Infect Dis; 2006 May; 42(9):1266-73. PubMed ID: 16586386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Brucella melitensis infection in mice by use of liposome-encapsulated gentamicin.
    Hernández-Caselles T; Vera A; Crespo F; Villalaín J; Gómez-Fernández JC
    Am J Vet Res; 1989 Sep; 50(9):1486-8. PubMed ID: 2802318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of some new antibiotics in treating experimental brucellosis].
    Maletskaia OV
    Antibiot Khimioter; 2002; 47(11):13-7. PubMed ID: 12698575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical and biological factors in the control of Brucella and brucellosis.
    Gamazo C; Lecároz MC; Prior S; Vitas AI; Campanero MA; Irache JM; Blanco-Prieto MJ
    Curr Drug Deliv; 2006 Oct; 3(4):359-65. PubMed ID: 17076637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.